日本 HCV 基因 4 型感染和肝硬化患者经 Glecaprevir 和 Pibrentasvir 联合治疗获得成功。
Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir.
机构信息
Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan.
Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan.
出版信息
Intern Med. 2021 Jul 1;60(13):2061-2066. doi: 10.2169/internalmedicine.6728-20. Epub 2021 Feb 1.
A 74-year-old man with a history of transfusion at 35 years old in Egypt was referred to our hospital. He was infected with hepatitis C virus (HCV) genotype 4 (GT4), which is a rare HCV GT in Japan, and was also diagnosed with hepatic compensated cirrhosis. We safely treated the patient for 12 weeks with the combination of glecaprevir and pibrentasvir, and a sustained virologic response (SVR) was achieved. This is the first report of HCV GT4 infection in a treatment-naïve Japanese patient with cirrhosis in whom SVR was achieved with the combination treatment of glecaprevir and pibrentasvir.
一位 74 岁男性，35 岁时在埃及有输血史，被转至我院。他感染了丙型肝炎病毒（HCV）基因 4 型（GT4），这在日本是一种罕见的 HCV GT，同时还被诊断为代偿性肝硬化。我们使用格卡瑞韦哌仑他韦联合治疗该患者 12 周，患者获得了持续病毒学应答（SVR）。这是首例日本初治肝硬化患者使用格卡瑞韦哌仑他韦联合治疗获得 SVR 的 HCV GT4 感染病例报告。
Zotero 插件